person · Reporting owner

Daskal Ilan

Disclosed activity across 4 companies

Tapewire entity: 18506
SEC CIK: 0001446964

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIO-RAD LABORATORIES, INC.BIO BIOB · Entity 2247	EVP, Chief Financial Officer	September 01, 2023	September 06, 2023
VIAVI SOLUTIONS INC.VIAV · Entity 3595	EVP, CFO	September 22, 2026	September 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIO-RAD LABORATORIES, INC.

Report date September 01, 2023 · Filed September 06, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,206.212	Reported balance After 2023-09-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-09-01 · Exercise / conversion · Acquired 694 · Balance 2,206.212 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. F2: Includes 18.9440 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2023.
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	1,966.212	Reported balance After 2023-09-01 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2023-09-01 · Tax withholding · Disposed 240 · Balance 1,966.212
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,422.212	Reported balance After 2023-09-01 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2023-09-01 · Exercise / conversion · Acquired 456 · Balance 2,422.212 F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,213.212	Reported balance After 2023-09-01 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2023-09-01 · Tax withholding · Disposed 209 · Balance 2,213.212
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,755.212	Reported balance After 2023-09-02 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2023-09-02 · Exercise / conversion · Acquired 542 · Balance 2,755.212 F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,486.212	Reported balance After 2023-09-02 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2023-09-02 · Tax withholding · Disposed 269 · Balance 2,486.212
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	4,007	Reported balance After 2023-09-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-01 · Grant · Acquired 4,007 · Balance 4,007 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	2,082	Reported balance After 2023-09-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-09-01 · Exercise / conversion · Disposed 694 · Balance 2,082 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5: On September 1, 2022, the reporting person was granted 2,776 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	912	Reported balance After 2023-09-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-09-01 · Exercise / conversion · Disposed 456 · Balance 912 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	542	Reported balance After 2023-09-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-09-02 · Exercise / conversion · Disposed 542 · Balance 542 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Class A common stock acquired on the vesting of restricted stock units.

F2: Includes 18.9440 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2023.

F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

F5: On September 1, 2022, the reporting person was granted 2,776 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

F6: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

F7: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

VIAVI SOLUTIONS INC.

Report date September 22, 2026 · Filed September 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	94,566	Ending reported balance After 2026-09-22 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-09-22 · Exercise / conversion · Acquired 82,671 · Balance 92,803 F1: Each stock unit converts upon vesting into one share of common stock. Row 2 · 2026-09-22 · Tax withholding · Disposed 37,285 · Balance 55,518 F2: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the market stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Row 3 · 2026-09-22 · Exercise / conversion · Acquired 71,127 · Balance 126,645 F1: Each stock unit converts upon vesting into one share of common stock. Row 4 · 2026-09-22 · Tax withholding · Disposed 32,079 · Balance 94,566 F2: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the market stock award. The amount retained by the Company was not in excess of the amount of the tax liability.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	55,115	Reported balance After 2026-09-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-22 · Exercise / conversion · Disposed 82,671 · Balance 55,115 F1: Each stock unit converts upon vesting into one share of common stock. F3: Shares reflect the vesting of the 2nd tranche of market-leveraged stock units granted on August 28, 2024 at 150.00% of target based on our total stockholder return during the performance periods as stated on the grant agreement. F4: There are no expiration dates on MSUs.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	94,840	Reported balance After 2026-09-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-22 · Exercise / conversion · Disposed 71,127 · Balance 94,840 F1: Each stock unit converts upon vesting into one share of common stock. F5: Shares reflect the vesting of the 1st tranche of market-leveraged stock units granted on August 28, 2025 at 150.00% of target based on our total stockholder return during the performance periods as stated on the grant agreement. F4: There are no expiration dates on MSUs.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	37,880	Reported balance After 2026-09-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-22 · Grant · Acquired 56,820 · Balance 37,880 F1: Each stock unit converts upon vesting into one share of common stock. F6: Represents the market stock units granted on November 28, 2023, which reflect the satisfaction of performance metrics. The market stock units vest on November 28, 2026, subject to continued service. F4: There are no expiration dates on MSUs.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	131,888	Reported balance After 2026-09-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-09-22 · Grant · Acquired 98,914 · Balance 131,888 F1: Each stock unit converts upon vesting into one share of common stock. F6: Represents the market stock units granted on November 28, 2023, which reflect the satisfaction of performance metrics. The market stock units vest on November 28, 2026, subject to continued service. F4: There are no expiration dates on MSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Each stock unit converts upon vesting into one share of common stock.

F2: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the market stock award. The amount retained by the Company was not in excess of the amount of the tax liability.

F3: Shares reflect the vesting of the 2nd tranche of market-leveraged stock units granted on August 28, 2024 at 150.00% of target based on our total stockholder return during the performance periods as stated on the grant agreement.

F4: There are no expiration dates on MSUs.

F5: Shares reflect the vesting of the 1st tranche of market-leveraged stock units granted on August 28, 2025 at 150.00% of target based on our total stockholder return during the performance periods as stated on the grant agreement.

F6: Represents the market stock units granted on November 28, 2023, which reflect the satisfaction of performance metrics. The market stock units vest on November 28, 2026, subject to continued service.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

IXIA

Report date April 18, 2017 · Filed April 20, 2017

Section 16 reporting ended · disclosed 2017-04-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-18 transaction · row 1 1 source row Row 1 · 2017-04-18 · Disposition to issuer · Disposed 16,140 · Balance 0 F1: On April 18, 2017 (the "Closing Date"), Keysight Technologies, Inc. ("Keysight") acquired the Issuer pursuant to the Agreement and Plan of Merger, dated as of January 30, 2017 (the "Merger Agreement"), by and among the Issuer, Keysight, and, by a joinder dated February 2, 2017, Keysight Acquisition, Inc., a wholly-owned subsidiary of Keysight ("Merger Sub"). On the Closing Date, in accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving the merger (the "Merger") as a wholly owned subsidiary of Keysight. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock outstanding immediately prior to the Effective Time (other than, if any, shares owned by Keysight or Merger Sub, or by any subsidiary of Keysight, Merger Sub, or the Issuer (except to the extent held on behalf of a third party)), was automatically cancelled and converted into the right to receive $19.65 per share in cash (the "per share merger consideration"), without interest and less any applicable withholding taxes required by law. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding immediately prior to the Effective Time automatically became fully vested and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such RSU and (b) the per share merger consideration, without interest and less any applicable withholding taxes required by law. The Merger is more fully described in the Issuer's definitive proxy statement filed with the SEC on March 14, 2017. F2: Represents (i) 13,712 shares of common stock owned directly and (ii) 2,428 shares of common stock subject to unvested RSUs that were outstanding immediately prior to the Effective Time. The unvested RSUs were scheduled to vest on May 15, 2017; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the RSUs would have vested at the close of business on the business day immediately preceding the date of such Meeting.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.55 · Expires 2022-06-01	Direct	Reported balance After 2017-04-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-04-18 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law. F4: Option to purchase 15,000 shares vested in 4 equal quarterly installments commencing August 15, 2015.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2023-06-01	Direct	Reported balance After 2017-04-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-04-18 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law. F5: Option to purchase 15,000 shares provided for vesting in 4 equal quarterly installments commencing August 15, 2016; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the final installment would have vested at the close of business on the business day immediately preceding the date of such Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: On April 18, 2017 (the "Closing Date"), Keysight Technologies, Inc. ("Keysight") acquired the Issuer pursuant to the Agreement and Plan of Merger, dated as of January 30, 2017 (the "Merger Agreement"), by and among the Issuer, Keysight, and, by a joinder dated February 2, 2017, Keysight Acquisition, Inc., a wholly-owned subsidiary of Keysight ("Merger Sub"). On the Closing Date, in accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving the merger (the "Merger") as a wholly owned subsidiary of Keysight. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock outstanding immediately prior to the Effective Time (other than, if any, shares owned by Keysight or Merger Sub, or by any subsidiary of Keysight, Merger Sub, or the Issuer (except to the extent held on behalf of a third party)), was automatically cancelled and converted into the right to receive $19.65 per share in cash (the "per share merger consideration"), without interest and less any applicable withholding taxes required by law. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding immediately prior to the Effective Time automatically became fully vested and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such RSU and (b) the per share merger consideration, without interest and less any applicable withholding taxes required by law. The Merger is more fully described in the Issuer's definitive proxy statement filed with the SEC on March 14, 2017.

F2: Represents (i) 13,712 shares of common stock owned directly and (ii) 2,428 shares of common stock subject to unvested RSUs that were outstanding immediately prior to the Effective Time. The unvested RSUs were scheduled to vest on May 15, 2017; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the RSUs would have vested at the close of business on the business day immediately preceding the date of such Meeting.

F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law.

F4: Option to purchase 15,000 shares vested in 4 equal quarterly installments commencing August 15, 2015.

F5: Option to purchase 15,000 shares provided for vesting in 4 equal quarterly installments commencing August 15, 2016; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the final installment would have vested at the close of business on the business day immediately preceding the date of such Meeting.

NATUS MEDICAL INC

Report date July 21, 2022 · Filed July 21, 2022

Section 16 reporting ended · disclosed 2022-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2022-07-21 transaction · row 1 1 source row Row 1 · 2022-07-21 · Disposition to issuer · Disposed 18,937 · Balance 0 F1: Disposed of pursuant to the previously announced Agreement and Plan of Merger, dated April 17, 2022, between Prince Parent Inc, Prince Mergerco Inc. and Issuer ("Merger Agreement"). F2: Each share of Common Stock was cancelled pursuant to the Merger Agreement in exchange for the right to receive the cash consideration provided in the Merger Agreement, subject to the applicable tax withholding.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the previously announced Agreement and Plan of Merger, dated April 17, 2022, between Prince Parent Inc, Prince Mergerco Inc. and Issuer ("Merger Agreement").

F2: Each share of Common Stock was cancelled pursuant to the Merger Agreement in exchange for the right to receive the cash consideration provided in the Merger Agreement, subject to the applicable tax withholding.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 04, 2021 Filed Aug 5, 2021 16:38 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	SaleBio-Rad A Common Stock	489	$753.32	$368,373.48	Disclosure SEC source: 0001062993-21-007078 · form4.xml · nonDerivative · entry 4 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $753.28 to $753.40, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 04, 2021 Filed Aug 5, 2021 16:38 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	SaleBio-Rad A Common Stock	954	$751.98	$717,388.92	Disclosure SEC source: 0001062993-21-007078 · form4.xml · nonDerivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $751.98 to $752.22, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 04, 2021 Filed Aug 5, 2021 16:38 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	SaleBio-Rad A Common Stock	857	$750.85	$643,478.45	Disclosure SEC source: 0001062993-21-007078 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,450 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.77 to $751.39, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 04, 2021 Filed Aug 5, 2021 16:38 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	1,400	$309.84	$433,776.00	Disclosure SEC source: 0001062993-21-007078 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 17, 2021 Filed Jun 21, 2021 17:02 UTC	NATUS MEDICAL INC NTUS · Entity 125256	GrantCommon Stock, $0.001 par value per share	5,214	$28.77	$150,006.78	Disclosure SEC source: 0000878526-21-000061 · wf-form4_162430934114115.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,862 F1 · shares: The shares vest in full on the first anniversary of the date of the award. Read SEC document
June 11, 2021 Filed Jun 15, 2021 17:02 UTC	NATUS MEDICAL INC NTUS · Entity 125256	SaleCommon Stock, $0.001 par vale per share	2,500	$27.46	$68,650.00	Disclosure SEC source: 0000878526-21-000053 · wf-form4_162379091694011.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,648 F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document
April 08, 2021 Filed Apr 9, 2021 15:38 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	700	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-21-003522 · form4.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Bio-Rad A Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document
April 08, 2021 Filed Apr 9, 2021 15:38 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	250	$592.23	$148,057.50	Disclosure SEC source: 0001062993-21-003522 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907 Read SEC document
April 08, 2021 Filed Apr 9, 2021 15:38 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	700	$0.00	$0.00	Disclosure SEC source: 0001062993-21-003522 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
September 02, 2020 Filed Sep 4, 2020 19:46 UTC	BIO-RAD LABORATORIES, INC. BIO,BIOB · Entity 2247	GrantNon-Qualified Stock Option (right to buy) · Derivative	2,166	$0.00 Strike: $524.30	$0.00	Disclosure SEC source: 0001812865-20-000016 · edgar.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166 Underlying: Bio-Rad A Common Stock · 2,166 shares Expires 2030-09-02 F3 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document
September 02, 2020 Filed Sep 4, 2020 19:46 UTC	BIO-RAD LABORATORIES, INC. BIO,BIOB · Entity 2247	GrantRestricted Stock Units · Derivative	2,166	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001812865-20-000016 · edgar.xml · derivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166 Underlying: Bio-Rad A Common Stock · 2,166 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document
June 19, 2020 Filed Jun 22, 2020 17:15 UTC	NATUS MEDICAL INC NTUS · Entity 125256	GrantCommon Stock, $0.001 par vale per share	3,560	$21.07	$75,009.20	Disclosure SEC source: 0000878526-20-000069 · wf-form4_159286053856924.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,148 F1 · shares: The shares vest in full on first anniversary of the date of the award. Read SEC document
April 08, 2020 Filed Apr 9, 2020 17:07 UTC	BIO-RAD LABORATORIES, INC. BIO,BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	700	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001315406-20-000004 · edgar.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Bio-Rad A Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning on April 8, 2020. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning on April 8, 2020. Read SEC document
April 08, 2020 Filed Apr 9, 2020 17:07 UTC	BIO-RAD LABORATORIES, INC. BIO,BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	243	$403.06	$97,943.58	Disclosure SEC source: 0001315406-20-000004 · edgar.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457 Read SEC document
April 08, 2020 Filed Apr 9, 2020 17:07 UTC	BIO-RAD LABORATORIES, INC. BIO,BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	700	$0.00	$0.00	Disclosure SEC source: 0001315406-20-000004 · edgar.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
March 18, 2020 Filed Mar 20, 2020 16:13 UTC	NATUS MEDICAL INC NTUS · Entity 125256	GrantCommon Stock, $0.001 par vale per share	7,588	$19.77	$150,014.76	Disclosure SEC source: 0000878526-20-000034 · wf-form4_158473516633446.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,588 F1 · shares: The shares vest in full on first anniversary of the date of the award. Read SEC document
April 08, 2019 Filed Apr 9, 2019 21:08 UTC	BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247	GrantNon-Qualified Stock Option (right to buy) · Derivative	3,500	$0.00 Strike: $309.84	$0.00	Disclosure SEC source: 0001652252-19-000008 · edgar.xml · derivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2029-04-08 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document
April 08, 2019 Filed Apr 9, 2019 21:08 UTC	BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247	GrantRestricted Stock Units · Derivative	3,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001652252-19-000008 · edgar.xml · derivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document
April 18, 2017 Filed Apr 20, 2017 18:01 UTC	IXIA XXIA · Entity 176851	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,000	Not disclosed Strike: $10.30	Not disclosed	Disclosure SEC source: 0001120295-17-000032 · edgar.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-06-01 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law. F5 · derivative.exercise_date: Option to purchase 15,000 shares provided for vesting in 4 equal quarterly installments commencing August 15, 2016; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the final installment would have vested at the close of business on the business day immediately preceding the date of such Meeting. Read SEC document
April 18, 2017 Filed Apr 20, 2017 18:01 UTC	IXIA XXIA · Entity 176851	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,000	Not disclosed Strike: $15.55	Not disclosed	Disclosure SEC source: 0001120295-17-000032 · edgar.xml · derivative · entry 2 Daskal Ilan · CIK 0001446964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-06-01 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law. F4 · derivative.exercise_date: Option to purchase 15,000 shares vested in 4 equal quarterly installments commencing August 15, 2015. Read SEC document
April 18, 2017 Filed Apr 20, 2017 18:01 UTC	IXIA XXIA · Entity 176851	Disposition to issuerCommon Stock	16,140	$19.65	$317,151.00	Disclosure SEC source: 0001120295-17-000032 · edgar.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On April 18, 2017 (the "Closing Date"), Keysight Technologies, Inc. ("Keysight") acquired the Issuer pursuant to the Agreement and Plan of Merger, dated as of January 30, 2017 (the "Merger Agreement"), by and among the Issuer, Keysight, and, by a joinder dated February 2, 2017, Keysight Acquisition, Inc., a wholly-owned subsidiary of Keysight ("Merger Sub"). On the Closing Date, in accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving the merger (the "Merger") as a wholly owned subsidiary of Keysight. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock outstanding immediately prior to the Effective Time (other than, if any, shares owned by Keysight or Merger Sub, or by any subsidiary of Keysight, Merger Sub, or the Issuer (except to the extent held on behalf of a third party)), was automatically cancelled and converted into the right to receive $19.65 per share in cash (the "per share merger consideration"), without interest and less any applicable withholding taxes required by law. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding immediately prior to the Effective Time automatically became fully vested and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such RSU and (b) the per share merger consideration, without interest and less any applicable withholding taxes required by law. The Merger is more fully described in the Issuer's definitive proxy statement filed with the SEC on March 14, 2017. F2 · shares: Represents (i) 13,712 shares of common stock owned directly and (ii) 2,428 shares of common stock subject to unvested RSUs that were outstanding immediately prior to the Effective Time. The unvested RSUs were scheduled to vest on May 15, 2017; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the RSUs would have vested at the close of business on the business day immediately preceding the date of such Meeting. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.